Massachusetts General Hospital researchers found individualized neoantigen therapy containing patient-specific mRNA-encoded instructions safe and effective in early trials, with potential for further research in other cancer types.

Massachusetts General Hospital researchers have demonstrated that an individualized neoantigen therapy (INT) containing patient-specific mRNA-encoded instructions is safe and effective in early trials. The therapy, mRNA-4157 (V940), induced multiple forms of T cell proliferation and maintained immune responses at later time points in a Phase I study of 16 patients with resected non-small cell lung cancer and cutaneous melanoma. The FDA granted a breakthrough therapy designation for mRNA-4157 (V940) in combination with pembrolizumab for melanoma treatment, potentially paving the way for further research in other cancer types.

August 08, 2024
6 Articles